Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 551 - 575 of 673 Clear search
Zyme Communications
18 Feb 2022

Centauri Therapeutics closes £24 million GBP Series A investment round

Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announces the close of its £24 million GBP (c. 32 million USD) Series A investment round.

Zyme Communications
15 Feb 2022

OxDX raises £2.6M pre-seed funding to develop AI powered rapid diagnostic technology

Technology aims to improve speed, cost and accuracy of infectious disease diagnostics. The funding will be used to expand team and further validate technology.

Zyme Communications
15 Feb 2022

Bio-Rad introduces anti-daratumumab antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38.

Zyme Communications
08 Feb 2022

Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer

Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic.

Zyme Communications
01 Feb 2022

Phico Therapeutics establishes Scientific Advisory Board

SAB will provide scientific oversight and strategic advice to support the progression Phico’s engineered phage antibacterial therapy, SASPject, through clinical trials.

Zyme Communications
01 Feb 2022

Bio-Rad launches Anti-Pertuzumab Antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, introduces four inhibitory antibodies that are highly specific to pertuzumab (Perjeta).

Zyme Communications
31 Jan 2022

Antiverse collaborates with top 20 pharma company to identify antibody drug candidates using AI Augmented Drug Discovery platform

Antiverse’s platform accurately identified diverse and rare antibodies. The project demonstrates potential of Antiverse’s platform to reduce time and costs associated with antibody drug discovery.

Zyme Communications
25 Jan 2022

H.E.L Group appoints Rajeev Kumria as General Manager of H.E.L India

Experienced General Manager and commercial leader will scale H.E.L's operations in Indian growth markets, including biotechnology, process safety, and pharmaceutical industries. The appointment will enable H.E.L India to provide direct sales and marketing, service, and support operations to customers locally.

Zyme Communications
18 Jan 2022

Avacta selects second pre|CISION™ pro-drug candidate for development

Cambridge and Wetherby, UK: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISION™ drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning…

Zyme Communications
13 Jan 2022

Insightful Science acquires Omiq to add cloud-based machine learning to its flow cytometry capabilities

OMIQ is a powerful flow cytometry SaaS solution adopted by leading global biopharma labs.

Zyme Communications
13 Jan 2022

The Native Antigen Company expands range of Norovirus-like particles

Oxford, UK: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the expansion of its norovirus-like particle range, with the addition of six new reagents, including four which are unique to the market. These virus-like…

Zyme Communications
11 Jan 2022

NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics

Shenzhen, China and Cambridge, UK: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and PhoreMost Limited (PhoreMost), the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, have announced an oncology drug discovery research collaboration.

Zyme Communications
11 Jan 2022

H.E.L Group expands operations in India

H.E.L India opening further strengthens H.E.L's global presence with regional hub-based service and customer support. Expansion will focus on supporting high growth industries in India, including biotechnology, process safety, and pharmaceutical industries

Zyme Communications
10 Jan 2022

Avacta provides update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, provides an update on the performance of the AffiDX® SARS-CoV-2 antigen lateral flow test (LFT) with the Omicron variant.

Zyme Communications
06 Jan 2022

Samsara Therapeutics establishes Scientific Advisory Board

Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics.

Zyme Communications
22 Dec 2021

Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test receives CE mark for consumer self-testing

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.

Zyme Communications
21 Dec 2021

Insightful Science acquires Protein Metrics to expand its R&D solution to include proteomics

San Diego, CA, 21 December 2021: Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire Protein Metrics Inc., a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the Company’s R&D value chain to widen the biopharmaceutical…

Zyme Communications
20 Dec 2021

Bio-Rad introduces Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays

HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex™ Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only (RUO). The assays allow scientists to measure neutralizing antibodies quickly and efficiently against wild-type and significant…

Zyme Communications
16 Dec 2021

Avacta announces AffiDx SARS-CoV-2 antigen lateral flow test detects the Omicron variant

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that the AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Zyme Communications
08 Dec 2021

FUJIFILM Irvine Scientific opens European manufacturing facility

SANTA ANA, California, December 8, 2021: FUJIFILM Irvine Scientific, Inc., today announced that  its new manufacturing facility in Tilburg, the Netherlands is now open and fully operational. The facility provides state-of-the-art Life Science manufacturing and joins locations in the U.S. and Japan to enable increased production capacity of cell culture media products; acting as a hub for…

Zyme Communications
02 Dec 2021

Sixfold Bioscience completes $10.5M USD (£7.8M GBP) seed financing

London, UK, 02 Dec 2021: Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery systems, today announced it has raised a total of $10.5 million USD (£7.8 million GBP) in its seed funding round. The funding will support the continued development of the Company’s Mergo® RNA therapeutics delivery platform.

Zyme Communications
29 Nov 2021

Avacta announces FDA approval of its Investigational New Drug (IND) application for AVA6000

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical…

Zyme Communications
17 Nov 2021

Rebeca Sanchez Sarmiento joins Insightful Science and Dotmatics as Chief Financial Officer

Appointment brings extensive financial industry experience to drive global growth and build corporate value of newly combined organization that is aiming to make the world a healthier, cleaner and better place to live.

Zyme Communications
16 Nov 2021

Bio-Rad introduces StarBright UltraViolet 400 Dye for flow cytometry

StarBright UltraViolet 400 Dye offers maximal brightness and narrow excitation and emission profiles for precise resolution.

Zyme Communications
11 Nov 2021

CrestOptics acquired by Apposite Capital LLP to enable rapid commercial growth and innovation in bioimaging

Investment from Apposite Capital LLP will accelerate CrestOptics’ commercial expansion into new markets globally, and enable further development of innovative cell imaging products.

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 21
  • Page 22
  • Current page 23
  • Page 24
  • Page 25
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS